AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

68.70USD
26 Nov 2014
Price Change (% chg)

$0.64 (+0.94%)
Prev Close
$68.06
Open
$68.36
Day's High
$68.84
Day's Low
$67.89
Volume
1,193,771
Avg. Vol
2,361,622
52-wk High
$68.84
52-wk Low
$45.51

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $109,470.10
Shares Outstanding (Mil.): 1,593.45
Dividend: 0.49
Yield (%): 2.85

Financials

  ABBV.N Industry Sector
P/E (TTM): 29.78 37.83 38.74
EPS (TTM): 2.31 -- --
ROI: 17.19 17.93 17.27
ROE: 90.29 18.73 18.18
Search Stocks

Europe gives green light to AbbVie hepatitis C drugs, others

LONDON - European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.

21 Nov 2014

Scuttled deals worth $580 bln put hedge funds on back foot

* Event driven funds lose $3.3 bln in outflows in two months

13 Nov 2014

AbbVie, Enanta drug shows potential in hep C genotype 4 patients

- AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

11 Nov 2014

AbbVie, Enanta drug shows potential in hep C genotype 4 patients

Nov 11 - AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

11 Nov 2014

Elliott Associates may sue AbbVie over scuttled deal

BOSTON - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

06 Nov 2014

UPDATE 1-Elliott Associates may sue AbbVie over scuttled deal

BOSTON, Nov 5 - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc for scuttling a merger deal with Shire Plc.

06 Nov 2014

Elliott Associates says mulls lawsuit against AbbVie - letter

BOSTON, Nov 5 - Elliott Associates, which suffered losses when a planned deal between pharmaceutical companies Shire PLC and AbbVie was scuttled last month, may take legal action against AbbVie Inc., the hedge fund told investors in its quarterly letter.

05 Nov 2014

US STOCKS-S&P 500 on track to end at record; BoJ move adds fuel to rally

* Indexes up: Dow 1 percent, S&P 1 percent, Nasdaq 1.3 percent (Updates to late afternoon)

01 Nov 2014

US STOCKS-Dow hits record high; BoJ ramps up stimulus

* Indexes up: Dow 1 percent, S&P 1 percent, Nasdaq 1.3 percent (Updates to early afternoon trading, changes byline)

31 Oct 2014

AbbVie says strong results lessen need for big deal

- AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire , reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long-term growth without rushing into another big merger attempt.

31 Oct 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $107.21 +0.51
Pfizer Inc. (PFE.N) $31.10 +0.63
Novartis AG (NOVN.VX) CHF93.00 +1.45
Merck & Co., Inc. (MRK.N) $59.75 +0.41
Roche Holding Ltd. (ROG.VX) CHF289.90 +2.80
Abbott Laboratories (ABT.N) $44.25 +0.09
Eli Lilly and Co (LLY.N) $67.32 +0.47

Earnings vs. Estimates

Search Stocks